New York Cancer & Blood Specialists’ Post

Excellent panel here.

❓ This question I am about to ask will not solicit a Yes or No response, your answer will most likely be a specific number or the name of the person; my mom, my daughter, my son, my dad, etc. ❔ The question isn't do you know someone impacted by cancer the reality is how MANY people do you know have died of cancer? Are battling cancer? Are thriving with cancer? 🌟 It is estimated that nearly 2 million people will get a cancer diagnosis in 2024 and the reality is we have only about 27 thousand oncologists in the United States to help them. Next month I will have my 🎥 , 🎤 & questions ready for the GOATS 🐐 and their mentees at the PrecisCa Fellow Forum. I am going to ask how do we build a sustainable oncology workforce and what advice can the KOL's give to the newbies about burnout rate within the profession. What do you want to know? 🤔 Let me know and I'll ask! Sherry Crowe thank you for creating a place where the newbies are supported, encouraged and guided. This helps all of us. #oncology #peeradvisory #cancerresearch #storytellingforbusiness #asktheexperts #asktherightquestions #videoproduction #newoncologists #expertoncologists

A new paper on equitable trial methodologies has been published in JAMA Oncology - VCCC Alliance https://lnkd.in/geYGKDV9 #oncodaily #oncology #cancer #research #JAMAOncology

Fortrea's expert panel will explore the current and future landscape of these CAR-T therapy, highlighting its diverse applications and potential. From revolutionizing treatment approaches in non-oncological diseases to leveraging operational oncology experience for broader therapeutic insights, this webinar will provide valuable lessons and insights into the transformative power CAR-T therapy across various therapeutics.

Innovation is so critical for now and in the future

Want an in-depth education covering a range of immunotherapy topics? Register for sessions covering disease states and topics of your choosing in the 2024 Advances in Cancer Immunotherapy™ Series: sitcancer.org/aci where you will receive expert training and the latest in clinical data. Also, the sessions are free to healthcare professionals, students, patients, and patient advocates. Brought in collaboration with SITC and the Advanced Practitioner Society for Hematology and Oncology, this series is certified for CME, CNE, CPE, and MOC credits, this series aims to provide what health professionals need to know to make informed, confident decisions when integrating immunotherapy treatments into clinical practice. Register today: sitcancer.org/aci! #immunotherapy #breastcancer #TILTherapy #CME #CNE #CPE

I want to thank patients, investigators and their staff for participating in our clinical trial with monotherapy #roginolisib, which was presented by #AnnaMariaDiGiacomo at this year´s Annual Meeting of the American Society of Clinical Oncology (#ASCO2024) in Chicago (see https://lnkd.in/dFpfc_cX; also see: ASCO® 2024 Insights: "Roginolisib, an Oral, Highly Selective and Allosteric Modulator of PI3Kd for Uveal Melanoma and Advanced Cancers" | VuMedi).  We are excited to learn more about the activity of roginolisib in patients with metastatic uveal melanoma as we continue to analyze the biomarker data from patients treated with #roginolisib. Such data will be presented at future medical conferences.

Sometimes its the simple things that can make a difference in patient experience. We are so excited that we have the ability to give subcutaneous trastuzumab (Herceptin)/pertuzumab (Perjeta) instead of IV in our #Nashville practice SCRI Oncology Partners. Article out today in JCO Oncology Practice about the impacts of sub-q administration vs. IV administration of these #HER2 agents. Spoiler alert ⚠: SQ trastuzumab/pertuzumab translated to over 1 hour less ⏰ chair time for patients at EACH administration. Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial) | JCO Oncology Practice (ascopubs.org)

🦾Breaking down barriers to quality cancer care! This is the mission that independent oncology physicians relentlessly pursue each day. ✍️Remember, when you walk into an independent oncology clinic, you're not a statistic, you're an individual. Each decision made is unique to your journey, your battle. It's about personalized care hinged not on standard protocols but on understanding your individual needs. 👩⚕️This is the power of being an independent oncology physician – the power to transform lives, one patient at a time.

Read the experts summary of recommendations on implementing #precision #oncology program #cancer #cancercare #cancerresearch #precisionmedicine